Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

A microbiological culture device including: a part made of absorbent material having an at least substantially planar upper face and incorporating into its thickness a dehydrated culture medium composition, resting on the part made of absorbent material, a sheet of dehydrated polysaccharide hydrogel which can be rehydrated at temperatures of between 5 C. and 40 C.; said sheet of dehydrated hydrogel being affixed directly on the upper face of the part made of absorbent material, or indirectly, through a permeable membrane insert.

Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

A water-soluble and/or water-swellable hybrid polymer comprising: (i) from 5 wt.-% to 95 wt.-% water-soluble and/or water-swellable polysaccharide polymer; (ii) from 5 wt.-% to 95 wt.-% synthetic polymer comprising: (a) from 40 mol-% to 99.9 mol-% repeating units according to Formula (1)

##STR00001## (b) from 0.01 mol-% to 5 mol-% crosslinking or branching units, wherein the crosslinking or branching units result from the incorporation of a monomer comprising at least two olefinically unsaturated double bonds; (c) from 0.01 mol-% to 88.51 mol-% of neutral structural units; (d) from 1.98 mol-% to 20 mol-% of anionic structural units, wherein the repeating anionic structural units result from the incorporation of a monomer comprising at least one carboxylate anion, and wherein the repeating anionic structural units are different from units (a);
wherein components (i) and (ii) are polymerized by radical precipitation polymerization in a polar solvent.

A water-soluble and/or water-swellable hybrid polymer comprising: (i) from 5 wt.-% to 95 wt.-% water-soluble and/or water-swellable polysaccharide polymer; (ii) from 5 wt.-% to 95 wt.-% synthetic polymer comprising: (a) from 40 mol-% to 99 mol-% of repeating units according to Formula (1)

##STR00001## (b) from 0.01 mol-% to 5 mol-% crosslinking or branching units, wherein the crosslinking or branching units result from the incorporation of a monomer comprising at least two olefinically unsaturated double bonds; (c) from 0.99 mol-% to 59.99 mol-% of repeating neutral structural units;
wherein components (i) and (ii) are polymerized by radical precipitation polymerization in a polar solvent.

A water-soluble and/or water-swellable hybrid polymer comprising: (i) from 5 wt.-% to 95 wt.-% water-soluble and/or water-swellable polysaccharide polymer; (ii) from 5 wt.-% to 95 wt.-% synthetic polymer comprising: (a) from 90 mol-% to 99.9 mol-%, preferably 95 mol-% to 99.5 mol-% of repeating units according to Formula (1)

##STR00001## (b) from 0.01 mol-% to 10 mol-%, preferably to 5 mol-%, more preferably to 3 mol-% of crosslinking or branching units, wherein the crosslinking or branching units result from the incorporation of a monomer comprising at least two olefinically unsaturated double bonds;
characterised in that the components (i) and (ii) are polymerised by radical precipitation polymerisation in a polar solvent.

Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

A water-soluble and/or water-swellable hybrid polymer comprising: (i) from 5 wt.-% to 95 wt.-% water-soluble and/or water-swellable polysaccharide polymer selected from the group consisting of xanthan gum, carrageenan, guar gum, chitosan, alginate and combinations thereof; (ii) from 5 wt.-% to 95 wt.-% synthetic polymer comprising up to 100 mol-% repeating units according to Formula (1a):

##STR00001##

wherein components (i) and (ii) are polymerized by radical precipitation polymerization in a polar solvent.

The present invention relates to a method for degrading a polysaccharide in the field of food, medicine or chemical industry. In particular, a molecular chain of the polysaccharide is broken by ozone into polysaccharides with smaller molecular weights, oligoses and/or oligosaccharides. The polysaccharides include linear or branched glycans extracted from plants, traditional Chinese medicinal materials, animals, fungi, or microorganisms and sulfated polysaccharides or esterified polysaccharides formed by sulfation or esterification thereof. As an oxidizing agent in the reaction, the ozone can be used alone or can be used under the catalysis of a base, a metal ion, hydrogen peroxide, UV light, or activated carbon to accelerate the reaction. The method for degrading the polysaccharide in the present invention uses milder reaction conditions compared to a conventional acid-catalytic degradation method, has higher reaction efficiency and a controllable reaction process, does not need to use an acid, and reduces environmental pollution.

A method for installing an in situ, low-permeability temporary horizontal barrier at depth for vertical containment of a soil mass including installing a low permeability vertical barrier having walls located to contain a predetermined soil volume, the vertical barrier having a horizontal surface area in a plane perpendicular to its walls; and injecting low permeability reagents capable of forming a temporary horizontal barrier in a pattern suitable for creating a horizontal subsurface barrier joined to all of the vertical barrier walls to form an in situ barrier.